Rizatriptan

Acute migraine with or without aura in adults and pediatric patients 6–17 years. Not indicated for prevention; cluster-headache safety/effectiveness are unestablished. Hemiplegic or basilar migraine is contraindicated under the label’s terminology. If the first treated attack fails to respond, reconsider the diagnosis before subsequent treatment; do not assume every severe headache is migraine.

Tablet is swallowed orally. MLT: dry hands, leave blister in outer pouch until dose, peel open rather than push; place on tongue, dissolve and swallow with saliva, without fluid. The label notes brand 5 mg tablet and MLT strengths are no longer marketed; prescribed 5 mg regimens require exact appropriately labeled product selection rather than an improvised split 10 mg MLT. Generic appearance, excipients and packaging need package verification. No parenteral, intranasal or routine preventive regimen inferred.

The selected label supplies exposure studies, not a universal renal/hepatic adjustment table: mild hepatic exposure was similar, moderate impairment increased levels about 30%; severe disease evidence is insufficient. CrCl 10–60 mL/min/1.73 m² did not significantly change exposure; hemodialysis patients (CrCl <2 in the same indexed units) had about 44% higher AUC. Do not invent a universal 5 mg ceiling or dialysis supplement from those observations. Older adults require cautious low-end selection, organ/medicine assessment and CV evaluation when risk factors apply.

Ischemic coronary artery disease or other significant underlying CV disease; coronary vasospasm; stroke/TIA history; peripheral vascular disease; ischemic bowel disease; uncontrolled hypertension; hemiplegic or basilar migraine; hypersensitivity including anaphylaxis/angioedema; another 5-HT1 agonist or ergot-containing medicine in the preceding 24 hours; concurrent MAO-A inhibitor or within 2 weeks of its discontinuation, including nonselective MAO inhibitors with MAO-A activity.

The selected Maxalt/MLT label has no boxed warning. Formal cardiovascular/vascular contraindications and potentially serious warnings still apply.

Common adult effects include fatigue, somnolence, dizziness and pain/pressure sensations; nausea and dry mouth can occur, with some dose dependence. Serious postmarketing reports include allergy, seizures and severe skin reactions with uncertain frequency. Overdose can cause syncope, bradycardia, vomiting, AV block, hypertension and coronary ischemia. Seek emergency/Poison Help (1-800-222-1222); clinical and ECG monitoring for at least 12 hours is advised even if asymptomatic. No specific antidote or known dialytic-removal benefit is established; no home gastric-emptying instructions.

Propranolol increases rizatriptan exposure; use the exact adult/pediatric reduced regimens above. This adjustment is not automatically applied to every beta blocker. MAO-A inhibitors increase parent/active-metabolite exposure and are contraindicated concurrently or within 2 weeks after stopping; nonselective MAO inhibitors are included.

Other triptans/5-HT1 agonists and ergot derivatives can produce additive vasospasm: avoid within 24 hours. SSRIs, SNRIs and other serotonergic drugs can cause serotonin syndrome; review the combination, counsel and monitor, while respecting formal MAO contraindications. No unsupported universal washout or CYP dose reduction is invented.

Ages 6–17 have weight-based single-dose labeling; below 6 safety/effectiveness unestablished. Pediatric propranolol restrictions are weight-specific, including no prescription below 40 kg. Older adults were underrepresented in trials; assess organ function, other drugs and cardiovascular risk, usually choosing the low end if appropriate.

Exposure data do not establish a universal adjustment algorithm; organ-specific limitations are described in dosage, and severe hepatic disease needs individual review. Preserve the label’s indexed renal units. PKU: check exact MLT phenylalanine amount; do not apply brand 10 mg content to all generic strengths.

Human pregnancy data and the historical 1998–2018 registry were too limited for reliable major-risk estimates; animal developmental toxicity informs counseling. The historical registry is not presented as a currently enrolling program. Human-milk transfer and infant effects are unknown in this label; consider maternal treatment need and breastfeeding benefits/risks. No invented milk-discard interval or safety guarantee supplied.

Rizatriptan has high affinity for 5-HT1B/1D receptors. Actions on cranial vessels and trigeminal sensory nerves are proposed to cause vasoconstriction and reduce pro-inflammatory neuropeptide signaling. It is an acute migraine treatment rather than a general analgesic or preventive drug.

Oral bioavailability is about 45%; tablet peak time roughly 1–1.5 hours, MLT approximately 0.7 hour later. Food can delay absorption without materially changing bioavailability. Half-life is about 2–3 hours. Primary metabolism is MAO-A oxidative deamination; an active N-monodesmethyl metabolite exists. Renal/hepatic and propranolol effects require the separately stated clinical restrictions, not an inferred PK-based self-adjustment.

Assess CV/vascular history, BP, prior triptan response, age/weight, propranolol/MAO/ergot/other triptan and serotonergic medicines, organ function and PKU formulation content. Track headache days and acute-treatment days; reassess insufficient response or medication overuse. No universal routine laboratory or ECG schedule for all users is asserted.

Use the prescribed single dose and population-specific limits. Children must not use adult repeat-dose instructions. Do not combine migraine medicines without review. Obtain urgent assessment for chest pain, stroke-like signs, severe abdominal pain/bloody diarrhea, severe allergy or serotonin toxicity. Dizziness/somnolence can impair driving; know individual effect. Keep MLT dry/in pouch until use, secure medicines from children and never share.

10 mg tablet

Pale-pink capsule-shaped tablet, MAXALT / MRK 267.

Selected package

18 tablets, NDC 78206-142-01.

Status

Prescription oral product; selected current label says brand 5 mg strengths no longer marketed.

Selected brand products

Maxalt 10 mg oral tablet; Maxalt-MLT 10 mg orally disintegrating tablet. Label retains 5 mg dose information but marks brand 5 mg products no longer marketed.

MLT identification

White/off-white round tablet with modified-square marking; 18-tablet carrying-case carton NDC 78206-143-01.

Ingredient versus salt

10 mg rizatriptan is supplied as 14.53 mg rizatriptan benzoate; clinical doses refer to rizatriptan.

Other products

Use exact generic 5 or 10 mg label/package for prescribed strength, imprint, phenylalanine and handling; no inventory or all-manufacturer appearance claim.

Selected tablet and MLT products store at 15–30°C. Keep MLT in sealed blister/outer aluminum pouch until immediately before use; dry hands and peel blister, do not push through foil. Protect from children and follow exact generic packaging directions.